Andere talen BioAtla, Inc.

Aandelen

BCAB

US09077B1044

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 27-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,47 ^USD	+4,26%		+3,89%	-40,24%

23/05	BioAtla, Inc. Presenteert fase 1 klinische onderzoeksgegevens van evalstotug die klinisch voordeel aantonen op de komende jaarlijkse bijeenkomst van de American Society of Clinical Oncology (ASCO) in 2024	CI
15/05	Exchange-Traded Funds Hoger, Aandelenfutures Gemengd Pre-Bell Woensdag Vooruitlopend op Belangrijke Inflatie, Retail Data	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024	27/06
BioAtla to Participate in the Jefferies Global Healthcare Conference	29/05
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05
BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	23/05
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	15/05
BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1	15/05
BioAtla : BCAB_Corp_Update_May 2024_FINALv3	14/05
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress	14/05
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
BioAtla to Participate in the Citizens JMP Life Sciences Conference	08/05
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024	07/05
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance	06/05
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	06/05
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	06/05
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26/03
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	19/03
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	07/03
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioAtla, Inc.

Aandelen

BCAB

US09077B1044

Andere talen

Filters